Theralase® Technologies will present at the 2026 ThinkEquity Conference in New York.
Our CEO, Roger DuMoulin-White, will discuss our EASM technology, clinical development programs, and upcoming corporate objectives.
Read: https://t.co/LhKrSwtZCg
🇨🇦 $TLT.V 🇺🇸 #TLTFF
Researchers from 3 universities are engineering light-activated smart nanoparticles to treat brain cancer.
At Theralase®, we welcome continued research into light-activated cancer treatments like our drug Ruvidar®.
More on Ruvidar®: https://t.co/M2JttiMn9g
🇨🇦 $TLT.V 🇺🇸 #TLTFF
Our anti-cancer drug Ruvidar® is ruthenium-based & is carried into CA cells the same way iron is delivered by blood proteins called transferrin.
Ruvidar® exploits CA cells' appetite for iron by targeting & then destroying them.
More: https://t.co/4FtNsfitvf
🇨🇦 $TLT.V 🇺🇸 #TLTFF
Why does Ruvidar® only affect cancer cells? Rutherrin® remains in healthy cells up to 20 min, while cancer cells may retain it for up to 3 days.
When activated, Ruvidar® is intended to destroy the cancer cells where it remains.
Read: https://t.co/T7x5hwWThQ
$TLT.V #TLTFF